Enhancing Patient Experience of Subcutaneous Administration in Oncology: Development of a Dedicated Patient-Reported Experience Measure (PREM) Questionnaire Based on a Structured and Collaborative Approach

Author(s)

Matthieu Plichart, MD1, Bianca Cheaib, MD2, Pernelle Lavaud, MD2, Corinne Urvoy, Directrice des soins1, Alessandro Viansone, MD2, Boris Duchemann, MD3, Antonio Di-Meglio, MD2, Mahasti SAGHATCHIAN, MD4, Nathalie Grémaud, PharmD5, Sandrine Bourguignon, MSc, PhD5, Nathalie BAILLON, .6, Alexandre Gherardi, .6, Sophie MICON, MSc6, Sarah Saget, .6, Julien Vercruyssen, .6, Mario Dipalma, MD2.
1Fondation Santé Service, Levallois-Perret, France, 2Institut Gustave Roussy, Villejuif, France, 3AP-HP, Paris, France, 4American Hospital of Paris, Neuilly-sur-Seine, France, 5Rweality, Paris, France, 6Roche SAS, Boulogne-Billancourt, France.
OBJECTIVES: Subcutaneous (SC) administration of certain targeted therapies and immunotherapies represents a promising alternative to intravenous infusion in oncology, particularly in breast and lung cancers. Despite its perceived convenience, the impact of the SC route on patient experience remains poorly documented, and no specific tool currently exists to capture this dimension. We report here the development of a dedicated PREM questionnaire as part of a broader initiative to evaluate SC administration in oncology.
METHODS: The PREM was co-developed through a structured and participatory process led by Roche in collaboration with Institut Gustave Roussy and Fondation Santé Service. A multidisciplinary working group contributed (oncologists, advanced practice nurses, unit managers from day hospital and home-based care, pharmacist, and nurse executive). Development steps included: (1) a targeted literature review to identify key domains; (2) French National Health Authority (HAS) guidelines on experience indicators; (3) a Delphi-inspired qualitative process involving two waves of interviews with professionals; (4) early patient involvement via individual interviews and an expert patient partner. The resulting tool was validated by an independent scientific committee.
RESULTS: The resulting PREM includes 21 items (16 closed-ended and 5 open-ended questions) exploring five dimensions: involvement in decision-making, communication quality, perception of SC administration, quality of care, and overall satisfaction. The questionnaire is designed to be applicable in both hospital and home care settings. Psychometric testing is planned as part of a forthcoming feasibility study.
CONCLUSIONS: This PREM fills an important gap in patient-centered evaluation of SC administration in oncology. It lays the groundwork for a systematic integration of patient voice into care planning and service organization. A pilot study is scheduled for 2025 at Institut Gustave Roussy and Fondation Santé Service, to assess feasibility and initiate broader dissemination of the tool.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

PCR74

Topic

Methodological & Statistical Research, Organizational Practices, Patient-Centered Research

Disease

Oncology

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×